Preclinical validation of a clinical prototype of intraoperative electron FLASH radiotherapy equipment: key evidence for a new radiotherapy paradigm.
[BACKGROUND AND PURPOSE] This study aimed to evaluate whether the clinical prototype of intraoperative electron FLASH radiotherapy (CPIO-EFLASH), with a source-surface distance (SSD) of 50 cm, could a
APA
Hao X, Du H, et al. (2025). Preclinical validation of a clinical prototype of intraoperative electron FLASH radiotherapy equipment: key evidence for a new radiotherapy paradigm.. Radiation oncology (London, England), 21(1), 19. https://doi.org/10.1186/s13014-025-02781-x
MLA
Hao X, et al.. "Preclinical validation of a clinical prototype of intraoperative electron FLASH radiotherapy equipment: key evidence for a new radiotherapy paradigm.." Radiation oncology (London, England), vol. 21, no. 1, 2025, pp. 19.
PMID
41437387
Abstract
[BACKGROUND AND PURPOSE] This study aimed to evaluate whether the clinical prototype of intraoperative electron FLASH radiotherapy (CPIO-EFLASH), with a source-surface distance (SSD) of 50 cm, could achieve ultra-high dose rates, effectively control tumors, and trigger the FLASH tissue-sparing effect in preclinical models.
[MATERIALS AND METHODS] Subcutaneous tumor-bearing mice (4T1 breast cancer, U87-MG glioma, PAN02 pancreatic cancer) and healthy C57BL/6 female mice (whole-brain, thorax, abdomen and single-leg irradiation) were subjected with ultra-high dose rate radiotherapy (UHDR-RT, ≥ 40 Gy/s), conventional doserate radiotherapy (CONV-RT,0.07 Gy/s), or sham radiotherapy (Control). We evaluated survival status, tumor growth suppression, apoptosis, proliferation, and DNA damage in tumor tissues, along with radiation-induced injuries to the brain, lung, intestine, and skin tissues.
[RESULTS] The actual dose rates of UHDR-RT ranged from 192 to 473 Gy/s. No significant difference in tumor growth suppression was observed between the UHDR-RT and CONV-RT. Two months post whole-brain irradiation, UHDR-RT demonstrated better spatial learning and memory abilities compared to CONV-RT. At 120 days post whole-thorax irradiation and 90 days post whole-abdomen irradiation, the survival rates of UHDR-RT were also significantly higher. Histological analyses revealed more severe injury to lung and intestinal tissues in the CONV-RT group. Additionally, UHDR-RT exhibited milder radiation-induced skin injury from 2 to 8 weeks post-irradiation.
[CONCLUSION] The CPIO-EFLASH can achieve ultra-high dose rates (≥ 40 Gy/s at an SSD of 50 cm) and trigger significant normal tissue-sparing effects. Integrating electronic FLASH technology into intraoperative radiotherapy may bring potential clinical benefits by effectively treating tumors, while minimizing radiation-induced injury to normal tissues. Our findings highlight the necessity for further clinical trials of CPIO-EFLASH in intraoperative radiotherapy.
[MATERIALS AND METHODS] Subcutaneous tumor-bearing mice (4T1 breast cancer, U87-MG glioma, PAN02 pancreatic cancer) and healthy C57BL/6 female mice (whole-brain, thorax, abdomen and single-leg irradiation) were subjected with ultra-high dose rate radiotherapy (UHDR-RT, ≥ 40 Gy/s), conventional doserate radiotherapy (CONV-RT,0.07 Gy/s), or sham radiotherapy (Control). We evaluated survival status, tumor growth suppression, apoptosis, proliferation, and DNA damage in tumor tissues, along with radiation-induced injuries to the brain, lung, intestine, and skin tissues.
[RESULTS] The actual dose rates of UHDR-RT ranged from 192 to 473 Gy/s. No significant difference in tumor growth suppression was observed between the UHDR-RT and CONV-RT. Two months post whole-brain irradiation, UHDR-RT demonstrated better spatial learning and memory abilities compared to CONV-RT. At 120 days post whole-thorax irradiation and 90 days post whole-abdomen irradiation, the survival rates of UHDR-RT were also significantly higher. Histological analyses revealed more severe injury to lung and intestinal tissues in the CONV-RT group. Additionally, UHDR-RT exhibited milder radiation-induced skin injury from 2 to 8 weeks post-irradiation.
[CONCLUSION] The CPIO-EFLASH can achieve ultra-high dose rates (≥ 40 Gy/s at an SSD of 50 cm) and trigger significant normal tissue-sparing effects. Integrating electronic FLASH technology into intraoperative radiotherapy may bring potential clinical benefits by effectively treating tumors, while minimizing radiation-induced injury to normal tissues. Our findings highlight the necessity for further clinical trials of CPIO-EFLASH in intraoperative radiotherapy.
MeSH Terms
Animals; Mice; Female; Electrons; Mice, Inbred C57BL; Radiotherapy Dosage; Humans; Mice, Inbred BALB C; Neoplasms
같은 제1저자의 인용 많은 논문 (5)
- Dual selective gleason pattern-aware multiple instance learning with uncertainty regularization for grade group prediction in histopathology images.
- Atorvastatin-Driven Methuosis in Glioblastoma: A Biomimetic Nanodrug for Targeted Tumor Therapy.
- Sanguinarine exerts anti-hepatocellular carcinoma activity by targeting FDX1 to induce FDX1/LIAS/DLAT/HSP70 axis-dependent cuproptosis.
- Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP Homeostasis.
- Lemon-Derived Extracellular Vesicles Engineered Oral Capsules for Enhanced Colorectal Cancer Chemotherapy by Mechanical Stress-Induced Intestinal Epithelial Barrier Opening.